Andrew Gottesdiener - 17 Jun 2025 Form 4 Insider Report for Apogee Therapeutics, Inc. (APGE)

Reporting relationship: Director
Issuer ticker: APGE
Reported as of: 17 Jun 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 20 Jun 2025, 20:02:14 UTC
Prior SEC filing: 07 Jun 2024
Next SEC filing: 10 Sep 2026
Source filing: View source filing
Reporting owner signature: /s/ Matthew Batters, as attorney-in-fact for Andrew Gottesdiener

Key filing fact

Andrew Gottesdiener filed Form 4 for Apogee Therapeutics, Inc. (APGE) on 20 Jun 2025.

Key facts

This page summarizes Andrew Gottesdiener's Form 4 filing for Apogee Therapeutics, Inc. (APGE).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 20 Jun 2025, 20:02.

Change

Previous filing in this sequence was filed on 07 Jun 2024.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001972292 Primary reporting owner

Gottesdiener Andrew

Relationship: Director
Address: C/O APOGEE THERAPEUTICS, INC., 221 CRESCENT ST., BLDG. 17, STE. 102B, WALTHAM
Signature: /s/ Matthew Batters, as attorney-in-fact for Andrew Gottesdiener
Signature date: 20 Jun 2025

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

APGE transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +14,461
Change %
Price: $0.000000
Shares after: 14,461
Date: 17 Jun 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 14,461
Exercise price: $41.66
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

This option represents the right to purchase 14,461 shares of the Issuer's common stock and will vest on the one-year anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer on such vesting date.

Footnote F2

Under an agreement between the Reporting Person and VR Management, LLC (the "Management Company"), the Reporting Person is deemed to hold the reported option and the shares underlying the option for the sole benefit of the Management Company and must exercise the reported option solely upon the direction of the Management Company, which is entitled to the shares underlying the option. The Management Company may be deemed the indirect beneficial owner of the shares underlying the option, and the Reporting Person may be deemed the indirect beneficial owner of the reported shares underlying the option through his interest in the Management Company. The Reporting Person disclaims beneficial ownership of the reported shares except to the extent of his pecuniary interest therein.